PE20100371A1 - Agonistas del receptor s1p para el tratamiento de malaria cerebral - Google Patents

Agonistas del receptor s1p para el tratamiento de malaria cerebral

Info

Publication number
PE20100371A1
PE20100371A1 PE2009001210A PE2009001210A PE20100371A1 PE 20100371 A1 PE20100371 A1 PE 20100371A1 PE 2009001210 A PE2009001210 A PE 2009001210A PE 2009001210 A PE2009001210 A PE 2009001210A PE 20100371 A1 PE20100371 A1 PE 20100371A1
Authority
PE
Peru
Prior art keywords
treatment
cerebral malaria
receptor agonists
formulation
receptor
Prior art date
Application number
PE2009001210A
Other languages
English (en)
Inventor
Max Bachrach
Tamas Oravecz
Constance Ann Marjory Finney
Kevin Charles Kain
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41621568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PE20100371A1 publication Critical patent/PE20100371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE CONTIENE: A) UN AGONISTA DEL RECEPTOR DE LA ESFINGOSINA-1-FOSFATO (S1P) DE FORMULA (I) DONDE Rp ES FENILO SUSTITUIDO CON ALQUILO(C6-C18), CICLOALQUILO, HETEROARILO O HETEROCICLO, EN DONDE UN COMPUESTO PREFERIDO ES FTY720; Y B) UNA AGENTE ACTIVO ADICIONAL TALES COMO i) UN FARMACO ANTIMALARIA TAL COMO QUININA, QUINIDINA, ENTRE OTROS, ii) UN DIURETICO OSMOTICO TAL COMO MANITOL, UREA, ENTRE OTROS, iii) UN ANTICONVULSIVANTE TAL COMO DIAZEPAN, FENITOINA, FENOBARBITAL, ENTRE OTROS, iv) UN ANTIPIRETICO TAL COMO PARACETAMOL, v) UN ANTIOXIDANTE, O vi) UN ANTIINFLAMATORIO. DICHA FORMULACION SE PRESENTA COMO UNA FORMA DE DOSIFICACION PARA SU ADMINISTRACION TOPICA, TRANSDERMICA O INTRAVENOSA SIENDO UTIL EN EL TRATAMIENTO DE LA MALARIA CEREBRAL
PE2009001210A 2008-10-31 2009-10-28 Agonistas del receptor s1p para el tratamiento de malaria cerebral PE20100371A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10999108P 2008-10-31 2008-10-31
US22997009P 2009-07-30 2009-07-30

Publications (1)

Publication Number Publication Date
PE20100371A1 true PE20100371A1 (es) 2010-06-01

Family

ID=41621568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001210A PE20100371A1 (es) 2008-10-31 2009-10-28 Agonistas del receptor s1p para el tratamiento de malaria cerebral

Country Status (12)

Country Link
US (1) US20100112037A1 (es)
EP (1) EP2349334A1 (es)
JP (1) JP2012507546A (es)
CN (1) CN102196820A (es)
AR (1) AR074062A1 (es)
AU (1) AU2009308843A1 (es)
CA (1) CA2741546A1 (es)
CL (1) CL2009002017A1 (es)
PE (1) PE20100371A1 (es)
TW (1) TW201021790A (es)
UY (1) UY32214A (es)
WO (1) WO2010051349A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159864A1 (en) * 2010-06-17 2011-12-22 Bracco Imaging S.P.A. Jte013 analogs and methods of making and using same
KR20130143091A (ko) 2010-11-22 2013-12-30 알러간, 인코포레이티드 치료적 유용성을 가지는 수용체 조절제로서의 신규한 화합물
US10022340B2 (en) 2013-10-11 2018-07-17 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
JP7174632B2 (ja) 2016-06-23 2022-11-17 コリウム， インコーポレイテッド 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
US20180028461A1 (en) * 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
EP3490541A2 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
WO2019245512A2 (en) * 2018-06-21 2019-12-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising fingolimod and at least one anti-epileptic agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
GB0411929D0 (en) * 2004-05-27 2004-06-30 Novartis Ag Organic compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TWI396677B (zh) * 2006-08-08 2013-05-21 Kyorin Seiyaku Kk An amine alcohol derivative and an immunosuppressive agent for use as an active ingredient
MX2009006751A (es) * 2006-12-21 2009-06-30 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato.
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
UY31013A1 (es) * 2007-04-12 2008-09-02 Lexicon Pharmaceuticals Inc Metodos para prepar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders

Also Published As

Publication number Publication date
UY32214A (es) 2010-05-31
CL2009002017A1 (es) 2011-01-07
CN102196820A (zh) 2011-09-21
TW201021790A (en) 2010-06-16
US20100112037A1 (en) 2010-05-06
AR074062A1 (es) 2010-12-22
JP2012507546A (ja) 2012-03-29
WO2010051349A1 (en) 2010-05-06
CA2741546A1 (en) 2010-05-06
EP2349334A1 (en) 2011-08-03
AU2009308843A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
PE20100371A1 (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
UY32602A (es) Formulación para la administración oral de un promotor de apoptosis
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CR20120663A (es) Combinaciones que comprenden antisicóticos atípicos y agonistas taar1
AR088383A1 (es) Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
PE20150345A1 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
AR095220A1 (es) Conjunto para un dispositivo de administración de fármacos
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
AR095194A1 (es) Conjunto para un dispositivo de administración de fármacos
AR092719A1 (es) Metodo y composicion para el tratamiento de ectoparasitos
JP2014530847A5 (es)
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
PE20160669A1 (es) Formas de dosificacion farmaceutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
PE20160038A1 (es) Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico
PE20100372A1 (es) Inhibidores de la s1p liasa para el tratamiento de malaria cerebral
RU2013142835A (ru) Способ лечения ишемического инсульта

Legal Events

Date Code Title Description
FC Refusal